Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

65.03USD
28 Aug 2015
Change (% chg)

-- (--)
Prev Close
$65.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
897,203
52-wk High
$72.31
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company's generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $61,908.67
Shares Outstanding(Mil.): 960.35
Dividend: 0.34
Yield (%): 2.59

Financials

  TEVA.N Industry Sector
P/E (TTM): 21.91 35.90 36.13
EPS (TTM): 2.97 -- --
ROI: 7.19 15.37 14.83
ROE: 10.94 15.94 15.69
Search Stocks

Mylan pursues Perrigo with lower shareholder support for takeover

NEW YORK, Aug 13 - Mylan NV, which is trying to buy drugmaker Perrigo Co through a hostile tender offer, on Thursday lowered the level of support it requires from Perrigo shareholders to push through the takeover.

13 Aug 2015

BRIEF-Allergan says experimental anti-depressant would serve "huge" market

* Allergan CEO, in conference call with analysts, says company will remain more of a "virtual" research company, relying mainly on licensing deals or acquisitions

06 Aug 2015

Perrigo CEO says no easy path for Mylan to acquire company

- Perrigo Co Plc on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.

05 Aug 2015

Perrigo CEO says no easy path for Mylan to acquire company

Aug 5 - Perrigo Co Plc on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.

05 Aug 2015

Healthcare deals lift July to 7th busiest M&A month on record

LONDON - A surge of takeover activity involving healthcare, financial and retail companies lifted the value of deals in July over $430 billion, making it the seventh-busiest mergers and acquisition month on record, Thomson Reuters data showed.

31 Jul 2015

Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM - Teva Pharmaceutical Industries , which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.

30 Jul 2015

Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM, July 30 - Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.

30 Jul 2015

RPT-Mylan independence from Teva's embrace comes with a price

July 27 - Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries, but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.

28 Jul 2015

PRESS DIGEST- Wall Street Journal - July 28

July 28 - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

28 Jul 2015

Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid

TEL AVIV - Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video

28 Jul 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF94.55 +0.35
Biogen Inc (BIIB.OQ) $303.69 --

Earnings vs. Estimates

Search Stocks